Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

7.01USD
8:22pm BST
Change (% chg)

$-1.63 (-18.92%)
Prev Close
$8.64
Open
$8.30
Day's High
$8.38
Day's Low
$6.94
Volume
298,266
Avg. Vol
49,965
52-wk High
$11.65
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Announces Completion Of Enrollment Of Phase 2 T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 T-REX CLINICAL TRIAL OF CLBS03 FOR TYPE 1 DIABETES.CALADRIUS BIOSCIENCES INC - TOPLINE DATA FROM PRIMARY ENDPOINT OF COMPLETED STUDY ON CLBS03 EXPECTED IN EARLY 2019.  Full Article

Caladrius Biosciences reports 2017 third quarter results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article

Caladrius Biosciences Q4 reports loss per share of $0.73
Friday, 17 Mar 2017 

Caladrius Biosciences Inc : Caladrius Biosciences announces 2016 fourth quarter and full year financial results . Q4 revenue rose 35 percent to $10.2 million . Q4 loss per share $0.73 .As of December 31, 2016, Caladrius had cash and cash equivalents of $14.7 million.  Full Article

Hitachi Chemical to buy remaining 80.1% interest in PCT from Caladrius
Thursday, 16 Mar 2017 

Hitachi Chemical Co Ltd <4217.T> :Hitachi chemical signs agreement to purchase from caladrius biosciences remaining 80.1% interest in percent for $75 million.  Full Article

Newhall Construction posts 13.48 pct passive stake in Caladrius Biosciences as of Sept. 14 - SEC Filing
Monday, 26 Sep 2016 

Caladrius Biosciences Inc:Newhall Construction Limited reports 13.48 percent passive stake in Caladrius Biosciences Inc, as of September 14, 2016 - SEC Filing.  Full Article

Caladrius Biosciences says sold $12.6 mln in equity financing
Monday, 26 Sep 2016 

Caladrius Biosciences Inc : Says it has sold $12.6 million in equity financing - SEC filing .Discloses in Form D with U.S. SEC that the total offering amount was for $21 million.  Full Article

Caladrius Biosciences receives FDA fast track designation
Thursday, 28 Jul 2016 

Caladrius Biosciences Inc : Caladrius Biosciences receives FDA fast track designation for CLBS03 to treat recent onset type 1 diabetes .CLBS03 is currently being studied in a landmark phase 2 clinical trial.  Full Article

Caladrius Biosciences in 1-for-10 reverse split
Wednesday, 27 Jul 2016 

Caladrius Biosciences Inc : Says announces 1-for-10 reverse split . Reverse stock split will be effective at 5:00 p.m., eastern time, on July 27, 2016 - sec filing . Reverse stock split intended to increase per share trading price of stock to satisfy $1 minimum bid price for continued listing on Nasdaq .Reverse stock split reduces number of shares outstanding from about 59 million pre-reverse split to about 5.9 million shares post-reverse split.  Full Article

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage: